Target-Specific Oral Anticoagulants

Apixiban (Eliquis®), Dabigatran (Pradaxa®), Rivaroxaban (Xarelto®)

CLINICAL SCREENING CHECKLIST

<table>
<thead>
<tr>
<th>Criteria for Target-Specific Oral Anticoagulant Use (all must be met)</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Non-valvular Atrial Fibrillation (AF) OR VTE prophylaxis for THA/TKA (rivaroxaban only) OR VTE treatment (rivaroxaban only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Creatinine Clearance (CrCl) &gt; 50 mL/min (dabigatran) Creatinine Clearance (CrCl) &gt; 30 mL/min (rivaroxaban and apixiban)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note that the GFR reported by lab medicine using MDRD equation is NOT CrCl. See equation below for calculating CrCl.

<table>
<thead>
<tr>
<th>3. If age &gt;75 years, prescriber will re-evaluate renal function at least annually to confirm CrCl exceeds those specified above in #2</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Prescriber has reviewed patient education with the patient and the patient prefers apixaban/dabigatran/rivaroxaban for anticoagulation therapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Patient is able to afford the cost of the medication, which even if covered by private insurance may be up to 50% of the cost of a 30 day supply</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*creatinine clearance, as calculated per Cockcroft-Gault equation using ideal body weight (IBW)*

\[
CrCl = \frac{(140 - \text{age}) \times (\text{IBW in kg}) \times 0.85 \text{ (females only)}}{72 \times (\text{serum creatinine})}
\]

\[
\text{IBW} = 50 \text{ kg} + (\text{height in inches} - 60) \times 2.3
\]

UW Medicine
Harborview Medical Center – UW Medical Center
Northwest Hospital & Medical Center – University of Washington Physicians
Seattle, Washington

TARGET-SPECIFIC ORAL ANTICOAGULANTS

*U3124*

*U3124*

WHITE - MEDICAL RECORD

UH3124 REV NOV 13